Trials / Completed
CompletedNCT02232425
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)
An 8-Week, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of IX-01 on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Lifelong Premature Ejaculation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Ixchelsis Limited · Industry
- Sex
- Male
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong premature ejaculation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IX-01 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2014-09-05
- Last updated
- 2020-08-17
- Results posted
- 2019-01-24
Locations
10 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT02232425. Inclusion in this directory is not an endorsement.